![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CP |
Gene summary for CP |
![]() |
Gene information | Species | Human | Gene symbol | CP | Gene ID | 1356 |
Gene name | ceruloplasmin | |
Gene Alias | CP-2 | |
Cytomap | 3q24-q25.1 | |
Gene Type | protein-coding | GO ID | GO:0000041 | UniProtAcc | A5PL27 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1356 | CP | GSM4909281 | Human | Breast | IDC | 2.40e-56 | 9.45e-01 | 0.21 |
1356 | CP | GSM4909282 | Human | Breast | IDC | 2.10e-17 | 3.80e-01 | -0.0288 |
1356 | CP | GSM4909290 | Human | Breast | IDC | 5.75e-06 | 3.01e-01 | 0.2096 |
1356 | CP | GSM4909295 | Human | Breast | IDC | 3.71e-03 | 2.70e-01 | 0.0898 |
1356 | CP | GSM4909307 | Human | Breast | IDC | 1.08e-14 | 4.03e-01 | 0.1569 |
1356 | CP | GSM4909308 | Human | Breast | IDC | 1.87e-13 | 3.49e-01 | 0.158 |
1356 | CP | brca2 | Human | Breast | Precancer | 2.58e-20 | 5.71e-01 | -0.024 |
1356 | CP | brca3 | Human | Breast | Precancer | 5.76e-10 | 3.76e-01 | -0.0263 |
1356 | CP | M2 | Human | Breast | IDC | 1.27e-14 | 1.04e+00 | 0.21 |
1356 | CP | NCCBC14 | Human | Breast | DCIS | 6.79e-06 | 4.61e-01 | 0.2021 |
1356 | CP | P2 | Human | Breast | IDC | 2.09e-14 | 7.78e-01 | 0.21 |
1356 | CP | DCIS2 | Human | Breast | DCIS | 2.37e-04 | 1.67e-01 | 0.0085 |
1356 | CP | CA_HPV_1 | Human | Cervix | CC | 1.12e-08 | -4.63e-01 | 0.0264 |
1356 | CP | CA_HPV_3 | Human | Cervix | CC | 3.97e-12 | -5.04e-01 | 0.0414 |
1356 | CP | HSIL_HPV_1 | Human | Cervix | HSIL_HPV | 4.70e-03 | -4.14e-01 | 0.0116 |
1356 | CP | N_HPV_1 | Human | Cervix | N_HPV | 6.31e-09 | -4.55e-01 | 0.0079 |
1356 | CP | N_HPV_2 | Human | Cervix | N_HPV | 2.75e-04 | -3.81e-01 | -0.0131 |
1356 | CP | CCII_1 | Human | Cervix | CC | 3.22e-04 | -4.98e-01 | 0.3249 |
1356 | CP | Tumor | Human | Cervix | CC | 5.04e-04 | -4.13e-01 | 0.1241 |
1356 | CP | sample1 | Human | Cervix | CC | 5.56e-11 | 7.38e-01 | 0.0959 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007149620 | Oral cavity | OSCC | cellular response to external stimulus | 186/7305 | 320/18723 | 2.56e-12 | 1.05e-10 | 186 |
GO:005082120 | Oral cavity | OSCC | protein stabilization | 122/7305 | 191/18723 | 2.69e-12 | 1.09e-10 | 122 |
GO:190018210 | Oral cavity | OSCC | positive regulation of protein localization to nucleus | 66/7305 | 87/18723 | 2.74e-12 | 1.10e-10 | 66 |
GO:19028506 | Oral cavity | OSCC | microtubule cytoskeleton organization involved in mitosis | 99/7305 | 147/18723 | 2.94e-12 | 1.18e-10 | 99 |
GO:190290520 | Oral cavity | OSCC | positive regulation of supramolecular fiber organization | 131/7305 | 209/18723 | 3.18e-12 | 1.27e-10 | 131 |
GO:00482852 | Oral cavity | OSCC | organelle fission | 265/7305 | 488/18723 | 3.22e-12 | 1.27e-10 | 265 |
GO:003462019 | Oral cavity | OSCC | cellular response to unfolded protein | 71/7305 | 96/18723 | 3.45e-12 | 1.35e-10 | 71 |
GO:190018015 | Oral cavity | OSCC | regulation of protein localization to nucleus | 93/7305 | 136/18723 | 3.46e-12 | 1.35e-10 | 93 |
GO:00161979 | Oral cavity | OSCC | endosomal transport | 141/7305 | 230/18723 | 5.40e-12 | 2.06e-10 | 141 |
GO:000756818 | Oral cavity | OSCC | aging | 194/7305 | 339/18723 | 6.18e-12 | 2.33e-10 | 194 |
GO:005105414 | Oral cavity | OSCC | positive regulation of DNA metabolic process | 126/7305 | 201/18723 | 8.12e-12 | 3.01e-10 | 126 |
GO:00070335 | Oral cavity | OSCC | vacuole organization | 115/7305 | 180/18723 | 1.11e-11 | 4.00e-10 | 115 |
GO:00070517 | Oral cavity | OSCC | spindle organization | 117/7305 | 184/18723 | 1.16e-11 | 4.17e-10 | 117 |
GO:000703410 | Oral cavity | OSCC | vacuolar transport | 103/7305 | 157/18723 | 1.25e-11 | 4.44e-10 | 103 |
GO:00365035 | Oral cavity | OSCC | ERAD pathway | 76/7305 | 107/18723 | 1.76e-11 | 6.11e-10 | 76 |
GO:19033139 | Oral cavity | OSCC | positive regulation of mRNA metabolic process | 82/7305 | 118/18723 | 1.77e-11 | 6.13e-10 | 82 |
GO:001095220 | Oral cavity | OSCC | positive regulation of peptidase activity | 123/7305 | 197/18723 | 2.12e-11 | 7.21e-10 | 123 |
GO:000166619 | Oral cavity | OSCC | response to hypoxia | 177/7305 | 307/18723 | 2.21e-11 | 7.50e-10 | 177 |
GO:19019905 | Oral cavity | OSCC | regulation of mitotic cell cycle phase transition | 173/7305 | 299/18723 | 2.49e-11 | 8.35e-10 | 173 |
GO:003298410 | Oral cavity | OSCC | protein-containing complex disassembly | 136/7305 | 224/18723 | 3.42e-11 | 1.13e-09 | 136 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0421642 | Breast | DCIS | Ferroptosis | 12/846 | 41/8465 | 4.69e-04 | 3.69e-03 | 2.72e-03 | 12 |
hsa0421652 | Breast | DCIS | Ferroptosis | 12/846 | 41/8465 | 4.69e-04 | 3.69e-03 | 2.72e-03 | 12 |
hsa0421614 | Cervix | CC | Ferroptosis | 14/1267 | 41/8465 | 1.75e-03 | 7.21e-03 | 4.26e-03 | 14 |
hsa0421615 | Cervix | CC | Ferroptosis | 14/1267 | 41/8465 | 1.75e-03 | 7.21e-03 | 4.26e-03 | 14 |
hsa0421629 | Esophagus | ESCC | Ferroptosis | 33/4205 | 41/8465 | 4.58e-05 | 1.99e-04 | 1.02e-04 | 33 |
hsa0421638 | Esophagus | ESCC | Ferroptosis | 33/4205 | 41/8465 | 4.58e-05 | 1.99e-04 | 1.02e-04 | 33 |
hsa042168 | Liver | NAFLD | Ferroptosis | 12/1043 | 41/8465 | 2.98e-03 | 2.96e-02 | 2.39e-02 | 12 |
hsa0421611 | Liver | NAFLD | Ferroptosis | 12/1043 | 41/8465 | 2.98e-03 | 2.96e-02 | 2.39e-02 | 12 |
hsa0421621 | Liver | Cirrhotic | Ferroptosis | 23/2530 | 41/8465 | 4.09e-04 | 2.57e-03 | 1.58e-03 | 23 |
hsa0421631 | Liver | Cirrhotic | Ferroptosis | 23/2530 | 41/8465 | 4.09e-04 | 2.57e-03 | 1.58e-03 | 23 |
hsa0421641 | Liver | HCC | Ferroptosis | 33/4020 | 41/8465 | 1.42e-05 | 9.88e-05 | 5.50e-05 | 33 |
hsa0421651 | Liver | HCC | Ferroptosis | 33/4020 | 41/8465 | 1.42e-05 | 9.88e-05 | 5.50e-05 | 33 |
hsa042169 | Lung | IAC | Ferroptosis | 11/1053 | 41/8465 | 9.62e-03 | 3.68e-02 | 2.44e-02 | 11 |
hsa0421612 | Lung | IAC | Ferroptosis | 11/1053 | 41/8465 | 9.62e-03 | 3.68e-02 | 2.44e-02 | 11 |
hsa0421620 | Oral cavity | OSCC | Ferroptosis | 29/3704 | 41/8465 | 4.26e-04 | 1.30e-03 | 6.60e-04 | 29 |
hsa04216110 | Oral cavity | OSCC | Ferroptosis | 29/3704 | 41/8465 | 4.26e-04 | 1.30e-03 | 6.60e-04 | 29 |
hsa0421643 | Oral cavity | NEOLP | Ferroptosis | 14/1112 | 41/8465 | 4.69e-04 | 2.71e-03 | 1.71e-03 | 14 |
hsa0421653 | Oral cavity | NEOLP | Ferroptosis | 14/1112 | 41/8465 | 4.69e-04 | 2.71e-03 | 1.71e-03 | 14 |
hsa0421618 | Prostate | BPH | Ferroptosis | 22/1718 | 41/8465 | 2.24e-06 | 2.00e-05 | 1.24e-05 | 22 |
hsa0421619 | Prostate | BPH | Ferroptosis | 22/1718 | 41/8465 | 2.24e-06 | 2.00e-05 | 1.24e-05 | 22 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CP | SNV | Missense_Mutation | novel | c.1843N>A | p.Gln615Lys | p.Q615K | P00450 | protein_coding | tolerated(0.28) | possibly_damaging(0.521) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
CP | SNV | Missense_Mutation | c.204G>T | p.Lys68Asn | p.K68N | P00450 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-A2-A25C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD | |
CP | SNV | Missense_Mutation | c.2285A>C | p.Asn762Thr | p.N762T | P00450 | protein_coding | deleterious(0.04) | benign(0.061) | TCGA-A8-A08R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CP | SNV | Missense_Mutation | c.1468N>C | p.Tyr490His | p.Y490H | P00450 | protein_coding | tolerated(0.5) | benign(0.003) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
CP | SNV | Missense_Mutation | c.616G>A | p.Asp206Asn | p.D206N | P00450 | protein_coding | tolerated(0.38) | benign(0.052) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CP | SNV | Missense_Mutation | c.2254N>A | p.Glu752Lys | p.E752K | P00450 | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CP | insertion | Nonsense_Mutation | novel | c.208_209insACTCATCGGACCTTTAATAATCTGTAAAAAAGGTACAT | p.Ala70AspfsTer6 | p.A70Dfs*6 | P00450 | protein_coding | TCGA-BH-A0BJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
CP | SNV | Missense_Mutation | novel | c.224A>G | p.Tyr75Cys | p.Y75C | P00450 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CP | SNV | Missense_Mutation | c.550N>A | p.Asp184Asn | p.D184N | P00450 | protein_coding | tolerated(0.09) | possibly_damaging(0.803) | TCGA-C5-A1MJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
CP | SNV | Missense_Mutation | c.572N>T | p.Ser191Leu | p.S191L | P00450 | protein_coding | deleterious(0) | possibly_damaging(0.88) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1356 | CP | DRUGGABLE GENOME, ENZYME | DEXRAZOXANE | DEXRAZOXANE | 8285144 | |
1356 | CP | DRUGGABLE GENOME, ENZYME | IMMUNOSUPPRESSIVE | 8406056 | ||
1356 | CP | DRUGGABLE GENOME, ENZYME | AMPICILLIN | AMPICILLIN | 1427966 | |
1356 | CP | DRUGGABLE GENOME, ENZYME | SODIUM MOLYBDATE | 7504610 | ||
1356 | CP | DRUGGABLE GENOME, ENZYME | TUMOR NECROSIS FACTOR | 2439635 | ||
1356 | CP | DRUGGABLE GENOME, ENZYME | ORAL CONTRACEPTIVE | 12616983 | ||
1356 | CP | DRUGGABLE GENOME, ENZYME | CLOMIPHENE CITRATE | 1692793 | ||
1356 | CP | DRUGGABLE GENOME, ENZYME | CELL SURFACE ANTIGEN | 9242695 | ||
1356 | CP | DRUGGABLE GENOME, ENZYME | PENICILLAMINE | PENICILLAMINE | 11721763 | |
1356 | CP | DRUGGABLE GENOME, ENZYME | PROGESTERONE | PROGESTERONE | 8619904 |
Page: 1 2 3 |